Neoclarityn (desloratadine)
- Region
- 🇪🇺 EU
- Active substance
- desloratadine
- Company
- Organon N.V.
- Status
- Authorised
- Therapeutic area
- Rhinitis, Allergic, Perennial; Urticaria; Rhinitis, Allergic, Seasonal
- CHMP opinion
- Thu 21 Sep 2000
- EU approval
- Mon 15 Jan 2001
- Application
- EMEA/H/C/000314
- ATC
- R06AX27
- Official record
- www.ema.europa.eu
Indication
Neoclarityn is indicated for the relief of symptoms associated with: allergic rhinitis urticaria
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Desloratadine Teva Authorised · Teva B.V
- 🇪🇺 Desloratadine ratiopharm Authorised · Ratiopharm GmbH
- 🇪🇺 Desloratadine Actavis Authorised · Actavis Group PTC ehf
- 🇪🇺 Dasselta Authorised · KRKA tovarna zdravil d.d. Novo mesto
- 🇪🇺 Aerinaze Authorised · Organon N.V.
- 🇪🇺 Aerius Authorised · Organon N.V.
- 🇪🇺 Azomyr Authorised · Organon N.V.
- 🇪🇺 Desloratadine Krka Application withdrawn · KRKA tovarna zdravil d.d. Novo mesto
- 🇪🇺 Allex Withdrawn · Schering-Plough Europe
- 🇪🇺 Opulis Withdrawn · Schering-Plough Europe
Follow Neoclarityn
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.